The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorub...

Descripción completa

Detalles Bibliográficos
Autores principales: Horwitz, S., O’Connor, O. A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K. J., Yuen, S., Zinzani, P. L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447792/
https://www.ncbi.nlm.nih.gov/pubmed/34921960
http://dx.doi.org/10.1016/j.annonc.2021.12.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447792/
https://www.ncbi.nlm.nih.gov/pubmed/34921960
http://dx.doi.org/10.1016/j.annonc.2021.12.002

Ejemplares similares